{
    "clinical_study": {
        "@rank": "48627", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 Progressors"
            }, 
            {
                "arm_group_label": "Cohort 2 - Non-Progressors"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective study to collect blood and bone marrow samples from patients with SM\n      and MGUS. About 100 subjects will be enrolled at the University of Pennsylvania and followed\n      for 2 years.  The primary objective of this study is to evaluate CMMCs as a biomarker to\n      detect patients at high risk of progression to multiple myeloma in patients with MGUS and\n      SMM."
        }, 
        "brief_title": "A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "a Diagnosis of MGUS or SMM by IMWG Criteria", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective is to evaluate CMMCs as a biomarker to detect patients at high risk of\n      progression to multiple myeloma in patients with MGUS and SMM.  The secondary objective are\n      to correlate CMMCs with the Mayo Clinic prognostic models in MGUS/SMM, to compare bone\n      marrow genomic findings with genomic findings in CMMC (utilizing multiple myeloma FISH\n      panel), to perform immunophenotyping of bone marrow plasma cells, to perform gene expression\n      profiling on CD138+bone marrow plasma cells and correlate with progression, to perform serum\n      microRNA profiling and correlate with progression, to correlate bone marrow\n      immunohistochemical studies evaluating the microenvironment with CMMC, to perform proteomic\n      profiling on peripheral blood to evaluate serum biomarkers of progression and to establish a\n      biorepository of samples of peripheral blood for future studies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years of age or older\n\n          -  Capable of informed consent\n\n          -  A monoclonal gammopathy detected in the serum (i.e. intact monoclonal immunoglobulin\n             IgG, IgA, IgM or biclonal).\n\n          -  Absence of myeloma related organ or tissue impairment (\"CRAB\") as defined by:\n\n        Hypercalcemia (calcium greater than or equal to 11), Renal Failure (creatinine >2.0),\n        Anemia hemoglobin  < 10 gm/dl, Bone disease (Osteolytic lesions, fractures)\n\n        Exclusion Criteria:\n\n          -  A secodnary B-cell neoplasm or other active malignancy aside from non-melanoma skin\n             cancer or localized prostate cancer. An active malignancy is any malignancy requiring\n             therapy within the past 3 years. Patients with monoclonal B-cell lymphocytosis are\n             not excluded.\n\n          -  Light chain only monoclonal gammopathy.\n\n          -  Inability to comply with follow-up."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male and Female subjects with diagnosis of MGUS or SMM by IMWG Criteria"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958528", 
            "org_study_id": "UPCC 28412"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 8, 2013", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Brendan Weiss, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Brendan Weiss, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Brendan Weiss, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Brendan Weiss, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to Progression", 
            "safety_issue": "Yes", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958528"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}